Welcome back,

CONFERENCE UPDATE

ESMO 2025

The European Society for Medical Oncology (ESMO) Congress 2025

October 17-21 , 2025 |

Berlin, Germany

2025

Osimertinib + plat-pem shows consistent OS benefits in EGFRm advanced NSCLC irrespective of poor baseline prognostic factors: Exploratory OS analyses from FLAURA2

ONCOLOGY
|
RESPIROLOGY

18 Dec 2025
Alectinib prolongs OS and shows durable response in previously untreated advanced ALK+ NSCLC: Final OS analysis from the phase 3 ALEX study
ONCOLOGY

20 Nov 2025
Adjuvant abemaciclib + ET reduces risk of death in HR+, HER2-, high-risk early breast cancer: Primary OS results from the monarchE trial

ONCOLOGY
|
OBSTETRICS & GYNECOLOGY

18 Nov 2025
Lenvatinib + pembrolizumab delivers sustained efficacy in aRCC regardless of baseline bone metastases: Final analysis from CLEAR

ONCOLOGY
|
NEPHROLOGY

7 Nov 2025
Initial results from the PATHFINDER 2 study highlight efficacy of multi-cancer early detection testing
ONCOLOGY

7 Nov 2025

eaa0190a-4510-467f-900f-c94c7b668484